anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a tilmicosin injection, and belongs to the technical field of veterinary drugs. The composition comprises tilmicosin, lactic acid, EDTA, DMF, propylene glycol and ethanol. The tilmicosin injection is used for treating bovine or porcine actinobacillus pleuropneumoniae, pasteurellosis, mycoplasma and other infections, such as bovine or porcine infectious pleuropneumonia, hemorrhagic septicemia and mycoplasma pneumonia. The administration is subcutaneous injection of 0.033ml per 1kg body weight. The tilmicosin injection of the invention has fast absorption after subcutaneous injection, strong tissue penetrating power and large distribution volume (more than 2L/kg). The concentration of the lung and the milk is high, the half-life period can reach 1 to 2 days, and the effective blood concentration can be maintained for a long time. Compared with the existing tilmicosin injection, the tilmicosin injection has better treatment effect.
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are well recognized for playing a dual role, since they can be either deleterious or beneficial to biological systems. An imbalance between ROS production and elimination is termed oxidative stress, a critical factor and common denominator of many chronic diseases such as cancer, cardiovascular diseases, metabolic diseases, neurological disorders (Alzheimer's and Parkinson's diseases), and other disorders. To counteract the harmful effects of ROS, organisms have evolved a complex, three-line antioxidant defense system. The first-line defense mechanism is the most efficient and involves antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). This line of defense plays an irreplaceable role in the dismutation of superoxide radicals (O2•-) and hydrogen peroxide (H2O2). The removal of superoxide radicals by SOD prevents the formation of the much more damaging peroxynitrite ONOO- (O2•-  + NO• → ONOO-) and maintains the physiologically relevant level of nitric oxide (NO•), an important molecule in neurotransmission, inflammation, and vasodilation. The second-line antioxidant defense pathway involves exogenous diet-derived small-molecule antioxidants. The third-line antioxidant defense is ensured by the repair or removal of oxidized proteins and other biomolecules by a variety of enzyme systems. This review briefly discusses the endogenous (mitochondria, NADPH, xanthine oxidase (XO), Fenton reaction) and exogenous (e.g., smoking, radiation, drugs, pollution) sources of ROS (superoxide radical, hydrogen peroxide, hydroxyl radical, peroxyl radical, hypochlorous acid, peroxynitrite). Attention has been given to the first-line antioxidant defense system provided by SOD, CAT, and GPx. The chemical and molecular mechanisms of antioxidant enzymes, enzyme-related diseases (cancer, cardiovascular, lung, metabolic, and neurological diseases), and the role of enzymes (e.g., GPx4) in cellular processes such as ferroptosis are discussed. Potential therapeutic applications of enzyme mimics and recent progress in metal-based (copper, iron, cobalt, molybdenum, cerium) and nonmetal (carbon)-based nanomaterials with enzyme-like activities (nanozymes) are also discussed. Moreover, attention has been given to the mechanisms of action of low-molecular-weight antioxidants (vitamin C (ascorbate), vitamin E (alpha-tocopherol), carotenoids (e.g., β-carotene, lycopene, lutein), flavonoids (e.g., quercetin, anthocyanins, epicatechin), and glutathione (GSH)), the activation of transcription factors such as Nrf2, and the protection against chronic diseases. Given that there is a discrepancy between preclinical and clinical studies, approaches that may result in greater pharmacological and clinical success of low-molecular-weight antioxidant therapies are also subject to discussion.
Participants randomised to the no treatment regimen will use the standard cleanser (only) twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours.
The invention relates to a liver carbuncle tetra-agent curing soup, which is prepared by mixing organic matters and minerals. The invention provides a medicine for curing liver carbuncle. The soup is prepared by the following raw materials by weight: 150 parts of white paeony root,100 parts of Chinese angelica, 9 parts of fried cape jasmine fruit, and 9 parts of raw liquorice. The invention overcomes the deficiencies in the prior art, and provides a medicine for treating both symptoms and root causes. The treatment is painless, has rapid efficacy, and is capable of curing liver carbuncle. The medicine has relation to the interests of thousands of households, has an important role in the country's economic development, can save tens of millions of people from pain, and can cure pneumonia, liver carbuncle, and purulent sores.
AIMS: The lymphocyte adaptor protein (LNK) is a negative regulator of cytokine and growth factor signalling. The rs3184504 variant in SH2B3 reduces LNK function and is linked to cardiovascular, inflammatory, and haematologic disorders, including stroke. In mice, deletion of Lnk causes inflammation and oxidative stress. We hypothesized that Lnk-/- mice are susceptible to atrial fibrillation (AF) and that rs3184504 is associated with AF and AF-related stroke in humans. During inflammation, reactive lipid dicarbonyls are the major components of oxidative injury, and we further hypothesized that these mediators are critical drivers of the AF substrate in Lnk-/- mice.
METHODS AND RESULTS: Lnk-/- or wild-type (WT) mice were treated with vehicle or 2-hydroxybenzylamine (2-HOBA), a dicarbonyl scavenger, for 3 months. Compared with WT, Lnk-/- mice displayed increased AF duration that was prevented by 2-HOBA. In the Lnk-/- atria, action potentials were prolonged with reduced transient outward K+ current, increased late Na+ current, and reduced peak Na+ current, pro-arrhythmic effects that were inhibited by 2-HOBA. Mitochondrial dysfunction, especially for Complex I, was evident in Lnk-/- atria, while scavenging lipid dicarbonyls prevented this abnormality. Tumour necrosis factor-α (TNF-α) and interleukin-1 beta (IL-1β) were elevated in Lnk-/- plasma and atrial tissue, respectively, both of which caused electrical and bioenergetic remodelling in vitro. Inhibition of soluble TNF-α prevented electrical remodelling and AF susceptibility, while IL-1β inhibition improved mitochondrial respiration but had no effect on AF susceptibility. In a large database of genotyped patients, rs3184504 was associated with AF, as well as AF-related stroke.
CONCLUSION: These findings identify a novel role for LNK in the pathophysiology of AF in both experimental mice and humans. Moreover, reactive lipid dicarbonyls are critical to the inflammatory AF substrate in Lnk-/- mice and mediate the pro-arrhythmic effects of pro-inflammatory cytokines, primarily through electrical remodelling.
The following study is intended to evaluate the efficacy and safety of an additional laser treatment for women previously treated for gynecological indications with laser treatments. Women will be randomized to one of 2 groups: 1. Study group-additional single laser treatment. 2. Control group-single sham laser treatment. All women will fill out validated questionnaires regarding sexual function, urinary stress incontinence and satisfaction after treatment. All women will be followed for an additional 6 months to evaluate the length of effect.
The application relates to the technical field of rose processing. The application discloses an extraction process of freeze-dried rose water and a rose cosmetic. The extraction process of the freeze-dried rose water comprises the following steps: s1, preprocessing, namely quick-freezing rose flowers for 5-8 hours; s2, carrying out vacuum freeze-drying treatment on the quick-frozen rose; s3, trapping the gas generated by sublimation in the step S2 by using a hydrazine cooling device, and rapidly condensing the gas into solid ice; s4, repeating the steps S2-S3 for 1-3 times; s5, melting the solid ice-like substance to obtain the freeze-dried rose water. The application discloses freeze-dried rose water prepared by the extraction process of the freeze-dried rose water. The application also discloses application of the freeze-dried rose water in cosmetics. The extraction process of the freeze-dried rose water provided by the application has the advantages that the whole process is in an ultralow-temperature environment, no high-temperature damage exists, the whole process of freeze-drying is in vacuum sealing, and the fragrance and active ingredients of the rose can be effectively reserved.
Waiting group will receive standard follow-up by their own LHWs. This group intervention will be documented at baseline, 3 months (end of the trial) and at 6 months. Similar training of Learning through Play will be provided to the mothers in this group at the end of the study.
<P>PROBLEM TO BE SOLVED: To provide a new member of tumor necrosis factor (TNF) family of cytokines, concretely an isolated nucleic acid molecule encoding an endokine α protein.  <P>SOLUTION: There are provided a new member of the tumor necrosis factor (TNF) family of cytokines, in particular, isolated nucleic acid molecules encoding the endokine α protein. There are also provided endokine α polypeptides, vectors, host cells and recombinant methods for producing these substances. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders. The method includes a step to administer an individual with a therapeutically effective amount of the endokine α polypeptide or a step to administer an individual with a therapeutically effective amount of an endokine α antagonist.  <P>COPYRIGHT: (C)2011,JPO&INPIT
BACKGROUND: Children with nephrotic syndrome are at risk of obesity and growth impairment from repeated steroid treatment. However, incidence and risk factors for obesity and short stature remain uncertain, which is a barrier to preventative care. Our aim was to determine risk, timing, and predictors of obesity and short stature among children with nephrotic syndrome.
METHODS: We evaluated obesity and longitudinal growth among children (1-18 years) enrolled in Insight into Nephrotic Syndrome: Investigating Genes, Health, and Therapeutics. We included children with nephrotic syndrome diagnosed between 1996-2019 from the Greater Toronto Area, Canada, excluding congenital or secondary nephrotic syndrome. Primary outcomes were obesity (body mass index Z-score ≥  + 2) and short stature (height Z-score ≤ -2). We evaluated prevalence of obesity and short stature at enrolment (< 1-year from diagnosis) and incidence during follow-up. Cox proportional hazards models determined the association between nephrotic syndrome classification and new-onset obesity and short stature.
RESULTS: We included 531 children with nephrotic syndrome (30% frequently relapsing by 1-year). At enrolment, obesity prevalence was 23.5%, 51.8% were overweight, and 4.9% had short stature. Cumulative incidence of new-onset obesity and short stature over median 4.1-year follow-up was 17.7% and 3.3% respectively. Children with frequently relapsing or steroid dependent nephrotic syndrome within 1-year of diagnosis were at increased risk of new-onset short stature (unadjusted hazard ratio 3.99, 95%CI 1.26-12.62) but not obesity (adjusted hazard ratio 1.56, 95%CI 0.95-2.56). Children with ≥ 7 and ≥ 15 total relapses were more likely to develop obesity and short stature, respectively.
CONCLUSIONS: Obesity is common among children with nephrotic syndrome early after diagnosis. Although short stature was uncommon overall, children with frequently relapsing or steroid dependent disease are at increased risk of developing short stature. Effective relapse prevention may reduce steroid toxicity and the risk of developing obesity or short stature.
Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. [see Contraindications, Tocolysis.]
Described is a new enzyme, 31-O-desmethylimmunomycin O-methyltransferase (DIMT) which can specifically and preferentially methylate the C-31 hydroxy group in immunomycin type molecules, also designated FK520 and FR-900520 by Fujisawa. The enzyme can be extracted out of the microorganism  Streptomyces   hygroscopicus  var.  ascomyceticus , (Merck Culture Collection No. MA 6678) ATCC No. 55087. Employing the enzyme in its active form, supplemented with Mg ⁺2 ion, in the presence of the methyl donor, S-adenosyl methionine (SAM), a new FK520 (FR-900520) derivative has been prepared: 15-desmethyl FR-900520, made from 15,31-bisdesmethyl FK-900520. This new macrolide can act as an antagonist at moderately low dosages and reverse the immunosuppressant action of FK-506, and can be used diagnostically as a tool to determine the presence of FK-506 macrolide type immunosuppressants in natural product broths, distinguishing such immunosuppressants from other chemical families such as the cyclosporins. Also, it can act as an agonist at higher dosages and much lower dosages and is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
The invention discloses a traditional Chinese medicine composition for tonifying kidney and spleen and a preparation method thereof. Belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following components in parts by mass: 80-90 parts of radix rehmanniae recen, 50-60 parts of Chinese yam, 50-60 parts of bighead atractylodes rhizome, 40-45 parts of radix scrophulariae, 40-45 parts of honeysuckle, 130-150 parts of rhizoma smilacis glabrae, 130-150 parts of lalang grass rhizome, 80-90 parts of moutan bark, 80-90 parts of eucommia bark, 40-45 parts of lotus rhizome node, 50-60 parts of endothelium corneum gigeriae galli, 130-140 parts of teasel root, 50-60 parts of Japanese thistle herb and 50-60 parts of herba cepbalanoplosis segeti. Compared with the prior art, the invention has the beneficial effects that: has obvious curative effect, can reduce the 24h urinary protein level of a rat with membranous nephritis, reduce the creatinine and urea nitrogen level, and improve the kidney pathology. Has the functions of invigorating kidney, invigorating spleen, clearing away heat and toxic material, promoting diuresis and stopping bleeding. The preparation process is reasonable, and the effective components of the medicinal materials are well reserved.
COPD encompasses a number of chronic lung disorders that obstruct the airways and may be accompanied by airway hyperactivity. The most common form of COPD is a combination of chronic bronchitis and emphysema. Many of the signs and symptoms associated with chronic bronchitis are a result of airway mucus hypersecretion induced by chronic inflammation of the airways. Clinically, mucus hypersecretion results in impaired gas exchange and compromised mucociliary clearance, encouraging bacterial colonization and associated exacerbations. A treatment that inhibits mucus hypersecretion or blocks inflammation could benefit COPD patients with chronic bronchitis. The drug under evaluation in this study, BIO 11006, is a new therapeutic agent that may inhibit mucus secretion and may have important anti inflammatory properties. In this study, BIO-11006 will be administered to COPD patients with chronic bronchitis, and the effects lung function will be assessed.
A device for vaporising a medicament (4). The device comprises a resistive element (9) on which the medicament is deposited. The device also comprises a source of electrical power which can be connected across the resistive element to vaporise the medicament. The element is configured to provide a central cool region (11) on which the medicament is deposited and a relatively hotter region (12) surrounding the cool region. Through holes (13) are also provided. The resistive element may be a mesh, foil or a tile on which a resistive pattern is deposited.
Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
Tea plant [Camellia sinensis (L.) O. Kuntze], as one of the most important commercial crops, frequently suffers from anthracnose caused by Colletotrichum camelliae. The plant-specific tau (U) class of glutathione S-transferases (GSTU) participates in ROS homeostasis. Here, we identified a plant-specific GST tau class gene from tea plant, CsGSTU45, which is induced by various stresses, including C. camelliae infection, by analyzing multiple transcriptomes. CsGSTU45 plays a negative role in disease resistance against C. camelliae by accumulating H2 O2 . JA negatively regulates the resistance of tea plants against C. camelliae, which depends on CsGSTU45. CsMYC2.2, which is the key regulator in the JA signaling pathway, directly binds to and activates the promoter of CsGSTU45. Furthermore, silencing CsMYC2.2 increased disease resistance associated with reduced transcript and protein levels of CsGSTU45, and decreased contents of H2 O2 . Therefore, CsMYC2.2 suppresses disease resistance against C. camelliae by binding to the promoter of the CsGSTU45 gene and activating CsGSTU45. CsJAZ1 interacts with CsMYC2.2. Silencing CsJAZ1 attenuates disease resistance, upregulates the expression of CsMYC2.2 elevates the level of the CsGSTU45 protein, and promotes the accumulation of H2 O2 . As a result, CsJAZ1 interacts with CsMYC2.2 and acts as its repressor to suppress the level of CsGSTU45 protein, eventually enhancing disease resistance in tea plants. Taken together, the results show that the JA signaling pathway mediated by CsJAZ1-CsMYC2.2 modulates tea plant susceptibility to C. camelliae by regulating CsGSTU45 to accumulate H2 O2 .
FIELD: medicine, pharmacy. SUBSTANCE: invention proposes wound-healing suppository containing thiotriazoline-morpholinium 3-methyl-1,2,4-triazolyl-5-thioacetate as an active component and solid fat, for example, hydrogenated sunflower oil as fatty basis. Suppository mass is 2.28-2.52 g, the content of thiotriazoline is 0.18-0.22 g and fat the balance. Suppository is used for treatment of erosive-ulcerous damages of rectum and vagina mucosa and hepatitis of different etiology also. Use of suppositories with thiotriazoline enhances effectiveness and reduces treatment period due to broad spectrum of biological activity of thiotriazolene and its high biological availability. EFFECT: enhanced effectiveness and valuable medicinal properties of suppository. 2 cl, 2 tbl
Everyday physical activities, such as walking, are enabled by repeated skeletal muscle contractions and require a well-functioning neuromuscular transmission. In myasthenic disorders, activities of daily living are debilitated by a compromised neuromuscular transmission leading to muscle weakness and fatiguability in patients. To enable physical activity, acetylcholine (ACh) is released repeatedly from the motor nerve, however, the role of the nerve terminals' capacity to sustain ACh release to support repetitive contractions under compromised neuromuscular transmission remains unclear. To explore this, we studied synaptic and contractile function during repeated contractions in healthy rat skeletal muscles under conditions of pharmacological induced compromised neuromuscular transmission. Using recordings of endplate potentials, compound muscle action potential (CMAP) and force production in isolated skeletal muscles and living, anesthetized animals, we found that force and CMAP were markedly reduced by even very light activity performed up to 5 s prior to contraction showing that recovery of ACh release was insufficient to maintain synaptic transmission strength. Our results suggest that the timing of depletion and restoration of ACh release may impact clinical signs of weakness and fatigability in patients with impaired neuromuscular transmission and affect the sensitivity of electromyographic recordings in the clinic.
The Smc5/6 complex is a highly conserved molecular machine involved in the maintenance of genome integrity. While its functions largely depend on restraining the fork remodeling activity of Mph1 in yeast, the presence of an analogous Smc5/6-FANCM regulation in humans remains unknown. We generated human cell lines harboring mutations in the NSE1 subunit of the Smc5/6 complex. Point mutations or truncations in the RING domain of NSE1 result in drastically reduced Smc5/6 protein levels, with differential contribution of the two zinc-coordinating centers in the RING. In addition, nse1-RING mutant cells display cell growth defects, reduced replication fork rates, and increased genomic instability. Notably, our findings uncover a synthetic sick interaction between Smc5/6 and FANCM and show that Smc5/6 controls fork progression and chromosome disjunction in a FANCM-independent manner. Overall, our study demonstrates that the NSE1 RING domain plays vital roles in Smc5/6 complex stability and fork progression through pathways that are not evolutionary conserved.
Aneurismal subarachnoid hemorrhage (aSAH) is a common disease in the neural system, with high death rate. Our study aimed to explore the clinical effect of external ventricular drainage under intracranial pressure monitoring in the treatment of patients with aSAH and investigate the role along with mechanism of miR-146a-5p in aSAH. Ninety-six aSAH patients were allocated into control group (CG) and study group (SG). The CG was released by lumbar puncture. The SG underwent external ventricular drainage based on intracranial pressure monitoring. The prognosis, daily living ability, neurological function, S100β and NSE (neuron-specific enolase) levels and incidence of complications were monitored. Besides, a rat model of SAH was built to assess the neurobehavioral function, blood-brain barrier permeability, brain water content, neuronal apoptosis as well as inflammation. SAH cell model stimulated by oxyhemoglobin, and cell apoptosis as well as inflammation were measured. Luciferase reporter assay was implemented to explore the interaction between miR-146a-5p and STC1. Results showed higher GOS and BI scores but lower NIHSS scores, S100β and NSE levels and complication rates in SG compared with CG. Additionally, miR-146a-5p presented down-regulation in brain tissues of SAH rat model, and overexpressed miR-146a-5p reduced brain injury along with neuroinflammation in SAH rat model. Oxyhemoglobin-induced nerve cell apoptosis along with inflammation after SAH, and overexpressed miR-146a-5p repressed oxyhemoglobin-induced nerve cell apoptosis along with inflammation. STC1 is the target mRNA of miR-146a-5p, and overexpressed miR-146a-5p represses oxyhemoglobin-induced nerve cell apoptosis along with inflammation via regulating STC1 expression. In conclusion, external ventricular drainage under intracranial pressure monitoring could promote prognosis, promote daily living ability, improve neurological function, reduce S100β protein and NSE levels, and reduce the incidence of complications in patients with aSAH. Meanwhile, miR-146a-5p inhibited early brain injury and neuroinflammation in aSAH via regulating STC1 expression.